<DOC>
	<DOCNO>NCT02987244</DOCNO>
	<brief_summary>The purpose study determine determine maximum tolerate dose ( MTD ) safety combination Chidamide combine CHOEP ( cyclophosphamide， epirubicin , vindesine , etoposide prednisone ) regimen first line treatment newly-diagnosed T-NHL .</brief_summary>
	<brief_title>Chidamide Plus CHOEP Combined With Upfront ASCT Untreated Peripheral T-cell Lymphoma</brief_title>
	<detailed_description>Chidamide+Cyclophosphamide+Epirubicin+Vindesine+Etoposide+Prednisone Six cycle therapy administer every 28 day plan . Cyclophosphamide 750mg/m2 IV d1 ; epirubicin 70mg/m2 IV d1 ; Vindesine 4mg IV d1 ; etoposide 100mg IV d1-3 ; prednisone 60mg/m2 PO d1-5 . Chidamide : Phase I : Patients treat follow bortezomib dose level : 15 , 20 , 25 mg twice per week . Dose escalation reduction basis continual reassessment method , least two patient per dose level dose level skip . No intrapatient dose escalation allow . If one patient experience dose-limiting toxicity ( DLT ) , three additional patient add dose level . If two six patient experienced DLT , previous dose level declare MTD . If one six patient experienced DLT , dose escalation permit continue . DLT refers toxic event occur first cycle treatment . At least 9 ( 3+3+3 ) patient enrol Phase I study . Phase II : If MTD reach 25mg dose level Chidamide . The followed study use 20mg twice per week experimental dose . After 3 Cycles , patient become PD withdraw trial receive regimen ; patient become CR eligible auto-SCT undergo auto-SCT ; patient get PR receive 3 cycle C-CHOEP regimen treatment , CR patient undergo auto-SCT , non-CR patient undergo follow-up phase . All patient continue receive chidamide treatment progression disease ( PD ) , unacceptable toxicity , patient/investigator discretion . During follow-uo phase , surveillance image CT scan perform every 6 month first 2 year , follow doctor visit every 6 month 5 year disease relapse . recruit first subject last recruited subject finish 2 year follow-up phase disease relapse</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>Newlydiagnosed T cell nonHodgkin 's lymphoma patient . Diagnosis T cell NHL perform morphologic analysis tissue pathological specimen along Immunohistochemistry ( IHC ) ECOG≤2 At least one unidimensionally measurable lesion ( ≥1 cm CT scan skin lesion measurable lesion physical examination ) Sign Informed consent Women childbearing potential must understand study medication could potential teratogenic risk . They undergo complete contraception study period . Male subject must agree use condom throughout study drug therapy . T lymphoblastic leukemia/lymphoma Bone marrow involvement lymphoma cell ≥ 25 % Aplastic large T cell lymphoma ALK positive NK/Tcell lymphoma Mycosis Fungoides/Sezary Syndrome Preexisting uncontrolled active infection Clinical evidence grade 3 4 heart failure define New York Heart Association criterion Grade 3 4 peripheral neuropathy Pregnancy active lactation Coexisting tumor Impaired renal/ hepatic function ( serum creatinine ＞1.5 mg/dl creatinine clearance ＜60 ml/min serum transaminases/ bilirubin ≥3 upper limit normal） History mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chidamide , T Cell Non-Hodgkin 's Lymphoma</keyword>
</DOC>